Palatin Technologies Completes Sale Of Vyleesi To Cosette Pharma For Up To $171 Mln
(RTTNews) - Biopharmaceutical company Palatin Technologies, Inc. (PTN) announced Wednesday the sale of Vyleesi to US-based speciality pharmaceutical company Cosette Pharmaceuticals for up to $171 million, consisting of an upfront purchase price of $12 million plus contingent, sales-based milestone payments of up to $159 million.
Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD).
Palatin will transfer to Cosette all information, data, and assets related exclusively to Vyleesi and provide certain transitional services to Cosette for a period of time to ensure continued patient access to Vyleesi.
Cosette will reimburse Palatin for the costs of the transition services. Palatin is also eligible to receive regulatory approval milestones of $10.5 million associated with the previous licensing of Vyleesi, consisting of $7.5 million related to Fosun for China and $3.0 million related to Kwangdong for S. Korea.
Palatin Technologies Says USPTO Issues Patent On Vyleesi For Hypoactive Sexual Desire Disorder
U.S. Consumer Sentiment Deteriorates Slightly More Than Initially Estimated In August
Chicago Business Barometer Slumps Much More Than Expected In August
U.S. Consumer Prices Increase In Line With Estimates In July
German Unemployment Exceeds 3 Mln
U.S. PCE Price Index Increased In Line With Estimates In July
Slightly Weak Start Seen For U.S. Stocks; PCE Data In Focus
